

UNITED STATES PATENT AND TRADEMARK OFFICE

BEFORE THE PATENT TRIAL AND APPEAL BOARD

REGENERON PHARMACEUTICALS, INC.,

Petitioner,

v.

NOVARTIS PHARMA AG, NOVARTIS TECHNOLOGY LLC,

NOVARTIS PHARMACEUTICALS CORPORATION,

Patent Owner.

IPR2021-00816

Patent 9,220,631 B2

Before ERICA A. FRANKLIN, ROBERT L. KINDER, and
KRISTIL R. SAWERT, *Administrative Patent Judges*.

KINDER, *Administrative Patent Judge*.

ORDER

Granting Petitioner's Motion for
Pro Hac Vice Admission of Robert Vlasits
37 C.F.R. § 42.10

IPR2021-00816
Patent 9,220,631 B2

On January 26, 2022, Petitioner filed a motion and supporting declaration for admission *pro hac vice* of Robert Vlasis. *See* Paper 44; Ex. 1098.

Having reviewed the motion and declaration, we conclude that Mr. Vlasis has sufficient qualifications to represent Petitioner in these proceedings, and that Petitioner has shown good cause for admission *pro hac vice* of Mr. Vlasis. *See Unified Patents, Inc. v. Parallel Iron, LLC*, IPR2013-00639, Paper 7 (PTAB Oct. 15, 2013) (order authorizing Motion for Admission *Pro Hac Vice*) (setting forth the requirements for admission *pro hac vice*). Mr. Vlasis will be permitted to appear *pro hac vice* as back-up counsel only. *See* 37 C.F.R. § 42.10(c).

A Power of Attorney has not been submitted for Mr. Vlasis. Accordingly, Petitioner must submit a Power of Attorney for Mr. Vlasis in accordance with 37 C.F.R. § 42.10(b), and must update its Mandatory Notices as required by 37 C.F.R. § 42.8(b)(3), to identify Mr. Vlasis as back-up counsel.

In consideration of the foregoing, it is hereby:

ORDERED that Petitioner's motion for admission *pro hac vice* of Robert Vlasis in this proceeding is *granted*, and Mr. Vlasis is authorized to represent Petitioner only as back-up counsel;

FURTHER ORDERED that Petitioner is to continue to have a registered practitioner as lead counsel in this proceeding;

FURTHER ORDERED that Mr. Vlasis is to comply with the Patent Trial and Appeal Board's Consolidated Trial Practice Guide (November 2019), *available at* <https://www.uspto.gov/TrialPracticeGuideConsolidated>,

IPR2021-00816
Patent 9,220,631 B2

and the Board's Rules of Practice for Trials, as set forth in Part 42 of Title 37, Code of Federal Regulations;

FURTHER ORDERED that Mr. Vlasis is subject to the USPTO's disciplinary jurisdiction under 37 C.F.R. § 11.19(a), and the USPTO's Rules of Professional Conduct set forth at 37 C.F.R. §§ 11.101–11.901;

FURTHER ORDERED that Petitioner shall submit, within ten (10) business days of the date of this order, a Power of Attorney for Mr. Vlasis in accordance with 37 C.F.R. § 42.10(b) in this proceeding; and

FURTHER ORDERED that Petitioner shall file an updated mandatory notice in this proceeding, within ten (10) business days of the date of this order, according to 37 C.F.R. § 42.8(b)(3), providing updated information regarding back-up counsel.

IPR2021-00816
Patent 9,220,631 B2

FOR PETITIONER:

Elizabeth Weiswasser
Anish Desai
Christopher Pepe
WEIL, GOTSHAL & MANGES LLP
elizabeth.weiswasser@weil.com
anish.desai@weil.com
christopher.pepe@weil.com

For PATENT OWNER:

Elizabeth Holland
William James
Linnea Cipriano
Joshua Weinger
Nicholas Mitrokostas
GOODWIN PROCTER LLP
eholland@goodwinprocter.com
wjames@goodwinlaw.com
lcipriano@goodwinlaw.com
jweinger@goodwinprocter.com
nmitrokostas@goodwinlaw.com